David Venables

David Venables has a diverse work experience spanning various companies and roles. David currently holds the position of CEO at Laverock Therapeutics since August 2021. David is also serving as a Non Executive Director at Axol Bioscience Ltd. since October 2021 and at NovalGen since March 2023.

In the past, David worked as the Managing Director of BioMelior Services Ltd starting from May 2013. David also held the position of Honorary Professor at The University of Edinburgh, College of Medicine & Veterinary Medicine, starting from May 2021.

Prior to these roles, David served as the President of AskBio Europe at Asklepios BioPharmaceutical, Inc. from January 2020 to August 2021. David was the CEO of Synpromics Ltd from October 2014 to January 2020, where they led a synthetic biology company specializing in synthetic promoters.

David has also worked as the VP - CMC at NightstaRx from August 2013 to June 2015, where they were responsible for pre-investment due diligence and CMC strategy definition. David served as the CEO of Anatara Lifesciences Ltd from October 2013 to February 2015, successfully leading the company's fundraising efforts and listing on the ASX.

Prior to that, David held multiple roles at Ark Therapeutics Plc, including Non Executive Director from April 2013 to February 2015, CEO from August 2012 to February 2015, and Executive Director - Manufacturing Services from April 2012 to August 2012. During their time at Ark Therapeutics, they led the company's strategic transition and achieved significant cost reduction and revenue growth.

David Venables obtained their Honours degree in Microbiology from the University of Surrey from 1986 to 1990. David then pursued their PhD in Mammalian cell fermentation from the same university, completing it from 1990 to 1993.